General Info

Abviva is a biomedical corporation focused on facilitating the development and marketing of novel diagnostics, therapeutics and niche products. The company's immediate development and acquisition efforts are focused on cancer diagnostics, therapeutics and neurodegenerative discoveries within the emerging field of proteomics. The company's development efforts are focused on novel cancer and neurodegenerative discoveries. Biomedical Diagnostics, a wholly owned subsidiary of Abviva, is developing proprietary cancer-screening products. The initial product-development effort is the commercialization of the Mammastatin Serum Assay (MSA) as a risk-screening diagnostic for breast cancer. Based on testing all women potentially at risk, there are more than 108 million women per year in the United States who could potentially benefit from having an MSA test done as part of their annual medical check-up. The company is headquartered in Surrey, British Columbia.